Scalper1 News
This is setting up to be a big year for specialty drugmaker DepoMed. After years of lumpy quarters driven by licensing deals with other drugmakers, DepoMed (DEPO) is coming into its own as an independent commercial pharma. It’s developed or acquired six approved products, most recently the regular and extended-release versions of pain medicine Nucynta, in a deal with Johnson & Johnson (JNJ) that closed April 2. Analysts expect 165% profit growth Scalper1 News
Scalper1 News